Choose Language

"Dedicated to giving our patients a promise for tomorrow"

BCG and ALT-803 for Non-Muscle Invasive Bladder Cancer

A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with Non-Muscle Invasive Bladder Cancer

NYU Winthrop  Hospital Department of Urology is conducting this clinical research study for men and women ages 18 and older who have biopsy proven Non-Muscle Invasive Bladder Cancer.  This study will evaluate the safety and efficacy of a drug called ALT-803 and Bacillus Calmette-Guerin (BCG) combination therapy in treating patients with Non-Muscle Invasive Bladder Cancer (bladder cancer that has not spread into the muscles of the bladder).  Participants will be randomly assigned to receive ALT-803 and BCG therapy or BCG therapy alone.  The drugs will be inserted into the bladder through a catheter (a tube inserted into the bladder).
 
To be eligible for this clinical research study you must:
·         Biopsy confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma subtype, intermediate or high-risk
·         Have adequate heart, lung, liver and kidney functions
 
For more information, you can read about this study on www.clinicaltrials.gov by searching for identifier NCT02138734 or contact our research coordinator at 516-535-1900 or UrologyResearch@nyuWinthrop.org.

Long Island Web Design